Prospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jun 21, 2023; 29(23): 3703-3714
Published online Jun 21, 2023. doi: 10.3748/wjg.v29.i23.3703
Table 1 Patients’ characteristics
Patients’ characteristics
n = 107
M/F61/46
Age (yr)55.1 ± 15.9
BMI (kg/m2)26.8 ± 4.1
Metabolic diseases
    Diabetes mellitus (yes/no)25/82
    Dyslipidemia (yes/no)35/72
    Hypertension (yes/no)37/70
Concomitant drugs
    SGLT2 inhibitor12
    DPP-4 inhibitor13
    Thiazolidinedione2
    GLP-1 agonist2
    Statin19
    Bezafibrate0
    Pemafibrate8
    EPA and DHA preparation1
AST (U/L)44.9 ± 38.0
ALT (U/L)70.6 ± 57.7
GGT (U/L)99.6 ± 139.7
T-B (mg/dL)0.9 ± 0.5
Alb (mg/dL)4.5 ± 0.4
eGFR (mL/min)73.0 ± 15.0
HbA1c (%)6.5 ± 1.2
T-chol (mg/dL)202.1 ± 52.6
TG (mg/dL)180.0 ± 119.0
WBC (103/μL)6731.8 ± 1882.5
Hb (g/dL)14.7 ± 1.3
Plts (104/μL)23.9 ± 7.6
Fib-4 index1.53 ± 1.90